drugset / Trial / NCT04409691
SCMC Trial on KHE With KMP (V.2020)
RandomizedParallel-groupOpen-labelTreatment
Summary
a phase I trial focusing on safety and efficacy of prednison shock plus sirolimus maintenance in treating Kaposiform hemangioendothelioma (KHE) with Kasabach-Merritt phenomenon (KMP)
Timeline
- Start
- 2020-07-01
- Primary completion
- 2023-01-31
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Prednisone | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | Sirolimus | Small molecule | 0.8 mg/m2 | Oral |